Aytu BioPharma, Inc.

NasdaqCM AYTU

Aytu BioPharma, Inc. Gross Profit for the Trailing 12 Months (TTM) ending September 30, 2024: USD 51.79 M

Aytu BioPharma, Inc. Gross Profit is USD 51.79 M for the Trailing 12 Months (TTM) ending September 30, 2024, a -18.30% change year over year. Gross profit is the difference between revenue and the cost of revenue, representing the profit earned from core business operations.
  • Aytu BioPharma, Inc. Gross Profit for the Trailing 12 Months (TTM) ending September 30, 2023 was USD 63.38 M, a 9.55% change year over year.
  • Aytu BioPharma, Inc. Gross Profit for the Trailing 12 Months (TTM) ending September 30, 2022 was USD 57.86 M, a 76.92% change year over year.
  • Aytu BioPharma, Inc. Gross Profit for the Trailing 12 Months (TTM) ending September 30, 2021 was USD 32.70 M, a 13.89% change year over year.
  • Aytu BioPharma, Inc. Gross Profit for the Trailing 12 Months (TTM) ending September 30, 2020 was USD 28.72 M, a 456.36% change year over year.
Key data
Date Gross Profit Operating Income EBIT EBITDA
Market news
Loading...
NasdaqCM: AYTU

Aytu BioPharma, Inc.

CEO Mr. Joshua R. Disbrow
IPO Date Sept. 25, 2008
Location United States
Headquarters 373 Inverness Parkway
Employees 102
Sector Health Care
Industries
Description

Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of ADHD in patients from 6 to 17 years old; and Adzenys ER, an oral suspension for the treatment of ADHD in patients from 6 years and older. It also provides Karbinal ER, a carbinoxamine oral suspension for the treatment of seasonal and perennial allergies; Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency; Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension; and ZolpiMist, an oral spray for the treatment of insomnia. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. was incorporated in 2015 and is headquartered in Englewood, Colorado.

Similar companies

SNOA

Sonoma Pharmaceuticals, Inc.

USD 2.64

2.33%

ESPR

Esperion Therapeutics, Inc.

USD 2.24

-1.75%

AVDL

Avadel Pharmaceuticals plc

USD 8.05

2.94%

IRWD

Ironwood Pharmaceuticals, Inc.

USD 3.65

-3.18%

LFCR

Lifecore Biomedical, Inc.

USD 6.43

1.10%

FLGC

Flora Growth Corp.

USD 0.94

1.68%

DERM

Journey Medical Corporation

USD 3.73

-1.32%

EVOK

Evoke Pharma, Inc.

USD 4.31

3.36%

AQST

Aquestive Therapeutics, Inc.

USD 3.05

-1.93%

SBFM

Sunshine Biopharma, Inc.

USD 2.82

-2.42%

StockViz Staff

January 15, 2025

Any question? Send us an email